Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Companion Medical's InPen Approved in Peds; BrightInsight Secures $40M Series B Funding

Here is a brief preview of this blast: Two diabetes-related items have been observed: Companion Medical announced FDA approval of its InPen for use in all ages and BrightInsight announced a Series B funding round of $40M. Below, FENIX provides thoughts on the expanded indication for InPen and BrightInsight's funding.